Literature DB >> 16585176

Growth and motility inhibition of breast cancer cells by epidermal growth factor receptor degradation is correlated with inactivation of Cdc42.

Dianne S Hirsch1, Yi Shen, Wen Jin Wu.   

Abstract

Overexpression of epidermal growth factor receptor (EGFR) contributes to increased cell proliferation and migration in breast cancer. However, mechanisms of EGFR overexpression remain elusive and often cannot be attributed to gene amplification. In NIH3T3 fibroblasts, active Cdc42 inhibits c-Cbl-regulated EGFR degradation to induce cellular transformation. Here, we use two EGFR-overexpressing breast cancer cell lines, MDA-MB-231 and BT20, as models to test the hypothesis that up-regulated Cdc42 activity impairs c-Cbl-mediated EGFR degradation and contributes to EGFR overexpression. We show that silencing Cdc42 significantly reduces protein levels of EGFR, leading to a marked reduction in cell proliferation and migration, and c-Cbl knockdown increases the levels of EGFR. Expression of c-Cbl-N480, a c-Cbl mutant that is not regulated by Cdc42 and blocks Cdc42-induced transformation but still binds and ubiquitinates EGFR, enhances the rate of EGFR degradation and subsequently inhibits cell proliferation. Moreover, down-regulated EGFR signaling induced by c-Cbl-N480 decreased activity of Cdc42 and Rac1, resulting in inhibition of cell migration. These findings indicate that Cdc42 and c-Cbl are critical components involved in the regulation of EGFR protein levels and that restoration of proper EGFR degradation by disrupting Cdc42 regulation of c-Cbl can reduce cell proliferation and migration in MDA-MB-231 and BT20 cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16585176     DOI: 10.1158/0008-5472.CAN-05-1547

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

1.  Rapid phospho-turnover by receptor tyrosine kinases impacts downstream signaling and drug binding.

Authors:  Laura B Kleiman; Thomas Maiwald; Holger Conzelmann; Douglas A Lauffenburger; Peter K Sorger
Journal:  Mol Cell       Date:  2011-09-02       Impact factor: 17.970

Review 2.  Cdc42 in oncogenic transformation, invasion, and tumorigenesis.

Authors:  Kristy Stengel; Yi Zheng
Journal:  Cell Signal       Date:  2011-04-16       Impact factor: 4.315

3.  T-DM1-resistant cells gain high invasive activity via EGFR and integrin cooperated pathways.

Authors:  Yukinori Endo; Yi Shen; Lamis Abou Youssef; Nishant Mohan; Wen Jin Wu
Journal:  MAbs       Date:  2018-09-11       Impact factor: 5.857

Review 4.  Pleiotropic functions of Rho GTPase signaling: a Trojan horse or Achilles' heel for breast cancer treatment?

Authors:  P R McHenry; T Vargo-Gogola
Journal:  Curr Drug Targets       Date:  2010-09       Impact factor: 3.465

5.  Plakophilin-2 promotes tumor development by enhancing ligand-dependent and -independent epidermal growth factor receptor dimerization and activation.

Authors:  Kei-ichiro Arimoto; Christoph Burkart; Ming Yan; Dan Ran; Stephanie Weng; Dong-Er Zhang
Journal:  Mol Cell Biol       Date:  2014-08-11       Impact factor: 4.272

6.  Clinicopathological pattern and Annexin A2 and Cdc42 status in patients presenting with differentiation and lymphnode metastasis of esophageal squamous cell carcinomas.

Authors:  Jun-Guo Feng; Qing Liu; Xu Qin; Yue-Hua Geng; Shu-Tao Zheng; Tao Liu; Ilyar Sheyhidin; Xiao-Mei Lu
Journal:  Mol Biol Rep       Date:  2011-05-21       Impact factor: 2.316

Review 7.  Targeting Cdc42 in cancer.

Authors:  Luis E Arias-Romero; Jonathan Chernoff
Journal:  Expert Opin Ther Targets       Date:  2013-08-19       Impact factor: 6.902

8.  Multipathway model enables prediction of kinase inhibitor cross-talk effects on migration of Her2-overexpressing mammary epithelial cells.

Authors:  Neil Kumar; Raffi Afeyan; Hyung-Do Kim; Douglas A Lauffenburger
Journal:  Mol Pharmacol       Date:  2008-03-18       Impact factor: 4.436

9.  CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.

Authors:  Yi-Hung Carol Tan; Soundararajan Krishnaswamy; Suvobroto Nandi; Rajani Kanteti; Sapana Vora; Kenan Onel; Rifat Hasina; Fang-Yi Lo; Essam El-Hashani; Gustavo Cervantes; Matthew Robinson; Han-Shui Hsu; Stephen C Kales; Stanley Lipkowitz; Theodore Karrison; Martin Sattler; Everett E Vokes; Yi-Ching Wang; Ravi Salgia
Journal:  PLoS One       Date:  2010-01-29       Impact factor: 3.240

10.  Autocrine-derived epidermal growth factor receptor ligands contribute to recruitment of tumor-associated macrophage and growth of basal breast cancer cells in vivo.

Authors:  Nicole K Nickerson; Christopher P Mill; Hsin-Jung Wu; David J Riese; John Foley
Journal:  Oncol Res       Date:  2013       Impact factor: 5.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.